BioNTech SE (BNTX) Research & Development (2018 - 2026)

BioNTech SE has reported Research & Development for 8 years, with the latest figure at -$588.3 million in Q4 2025.

• Quarterly Research & Development rose 10.01% year-over-year to -$588.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.4 billion (up 2.51% YoY) and the FY2025 annual result came in at $2.4 billion, down 1.27% from the prior year.
• Research & Development improved to -$588.3 million in Q4 2025 per BNTX's latest filing, from -$660.3 million in the prior quarter.
• Over five years, Research & Development peaked at -$242.2 million in Q2 2021 and troughed at -$660.3 million in Q3 2025.
• A 5-year average of -$473.9 million and a median of -$531.1 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2021 and 2025: Research & Development sank 101360660.56% in 2021, then grew 10.01% in 2025.
• Over 5 years, Research & Development stood at -$310.6 million in 2021, then plunged by 67.46% to -$520.1 million in 2022, then fell by 19.53% to -$621.7 million in 2023, then decreased by 5.16% to -$653.8 million in 2024, then grew by 10.01% to -$588.3 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered -$588.3 million, -$660.3 million, and -$576.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.